Selected Highlights from the 26th San Antonio Breast Cancer Symposium

Bibliography

• BAUM M, BUDZAR AU, CUZICK J et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet (2002) 359:2131–2139.
   PubMed Web of Science ®Google Scholar
• BAUM M, BUZDAR A, CUZICK J et al.: i Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer i (2003) 98:1802–1810.
   Google Scholar
• WINER EP, HUDIS C, BURSTEIN HJ et al.: i American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.' Clin. °pea i (2003) 21:2597–2599.
   Google Scholar
• DOWSETT M, SMITH I: Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res. Treat. i (2003) 82:S7 (Abstract 4).
   Google Scholar
• SMITH I, DOWSETT M: Comparison of anastrozole versus tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res. Treat. i (2003) 82:S6 (Abstract 1).
   Google Scholar
• DOWSETT M, SMITH I: Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) than with tamoxifen (T) or anastrozole plus tamoxifen(C) in the IMPACT trial: a potential predictor of relapse-free survival. Breast Cancer Res. Treat. i (2003) 82:S6(Abstract 2).
   Google Scholar
• BOCCARDO F, RUBAGOTTI A, AMOROSO D et al.: i Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. Clin. °pea i (2001) 19:4209–4215.
   Google Scholar
• GOSS PE, INGLE JN, MARTINO S et al.: i A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl. i Med(2003) 349:1793–1802.
   PubMed Web of Science ®Google Scholar
• NABHOLTZ JM, PIENKOWSKI T, MACKEY J et al: i Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorbicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. PrOC. Am. Soc. Clin. °pea i (2002) 21:36a (Abstract 141).
   Google Scholar
• MARTIN M, RODRIGUEZ-LESCURE A, RUIZ A et al.: i Multicenter, randomized Phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC versus 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: first safety analysis of GEICAM 9906 trial. Breast Cancer Res. Treat. i (2003) 82:S29 (Abstract 136).
   Google Scholar
• ROCHE H, SPIELMANN M, FUMOLEAU P et al.: i Safety analysis of the PACS 01 adjuvant trial comparing 6 cycles of FEC 100 to 3 cycles of FEC 100 followed by 3 cycles of docetaxel (Taxotere9 for node positive breast cancer. Breast Cancer Res. Treat. i (2003) 82:S32 (Abstract 144).
   Google Scholar
• KUERER HM, NEWMAN LA, SMITH TL et al.: i Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. Clin. °heel i (1999) 17:460–469.
   Google Scholar
• HUTCHEON AW, HEYS SD, SARKAR TK et al.: i Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res. Treat. i (2003) 82:S9 (Abstract 11).
   Google Scholar
• SMITH IC, HEYS SD, HUTCHEON AW et al.: i Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Clin. °pea i (2002) 20:1456–1466.
   Google Scholar
• JONES S, ERBAN J, OVERMOYER B et al.: i Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res. Treat. i (2003) 82:S9 (Abstract 10).
   Google Scholar
• DESAI N, YAO Z, TRIEU V et al: i Evidence of superior tumor and red cell988 partitioning and superior antitumor activity of Cremophor-free nanoparticle paclitaxel (ABI-007) compared to taxol. Breast Cancer Res. Treat. i (2003) 82:S82 (Abstract 348).
   Google Scholar
• IBRAHIM N, SAMUELS B, PAGE R et al.: i Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): efficacy and evidence of dose-dependent activity in two multicenter Phase II studies. Proc. Am. Soc. Clin. Oncol i (2002) 21:53a(Abstract 209).
   Google Scholar
• MONTEMURRO F, VALABREGA G, AGLIETTA M: Trastuzumab-based combination therapy for breast cancer. Expert Opin. Pharmacother. i (2004) 5:81–96.
   PubMed Web of Science ®Google Scholar
• CHANG JC, MOHSIN S, WEISS H et al.: i Induction of apoptosis without change in cell proliferation in primary breast cancers with neoadjuvant trastuzumab. Breast Cancer Res. Treat. i (2003) 82:S13(Abstract 24).
   Google Scholar
• VAN PELT AE, MOHSIN S, ELLEDGE RIVI et al.: i Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin. Breast Cancer i (2003) 4:348–353.
   PubMedGoogle Scholar
• GEYER CEJ, BRYANT J, ROMOND E et al.: i Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). Breast Cancer Res. Treat. i (2003) 82:S13 (Abstract 23).
   Google Scholar
• LEVIN ER Estrogen Signalling from the plasma membrane in breast cancer. Breast Cancer Res. Treat. i (2003) 82:S3 (Abstract M53–2).
   Google Scholar
• JOHNSTON SRD Molecular insights into endocrine resistance - implications for future therapies. Breast Cancer Res. Treat. i (2003) 82:S4 (Abstract M53–4).
   Google Scholar
• PIETRAS RJ, MARQUEZ DC, CHEN H-W et al.: i Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res. Treat. i (2003) 82:S12 (Abstract 22).
   Google Scholar
• BHARWANI L, SCHIFF R, MOHSIN SK et al.: i Inhibiting the EGFR/HER2 pathway with gefitinib and/or trastuzumab restores tamoxifen sensitivity in HERZ- overexpressing tumors. Breast Cancer Res. Treat. i (2003) 82:S13 (Abstract 25).
   Google Scholar
• WONG ZW, ISAACS C, HARRIS L et al.: iA Phase II trial of letrozole and trastuzumab for ER and/or PgR and HERZ positive metastatic breast cancer. Breast Cancer Res. Treat. i (2003) 82:S106 (Abstract 444).
   Google Scholar
• ATALAY G, CARDOSO F, AWADA A et al.: i Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann. Oncol i (2003) 14:1346–1363.
   PubMed Web of Science ®Google Scholar
• KONECNY G, FINN R, VENKATESAN N et al.: i The novel dual kinase inhibitor GW572016 is particularly active in HER2-positive and trastuzumab-conditioned breast cancer cells. Breast Cancer Res. Treat. i (2003) 82:S171 (Abstract 1010).
   Google Scholar
• BURRIS HA, HURWITZ H, DEES C et al: i EGF10004: a randomized, multicenter, Phase lb study of the safety, biologic activity and clinical efficacy of the dual kinase inhibitor GW572016. Breast Cancer Res. Treat. i (2003) 82:S18 (Abstract 39).
   Google Scholar
• HOLMBERG LA, SANDMAIER BM: Theratope vaccine (STn-KLH). Expert Opin. Biol. Ther. i (2001) 1:881–891.
   PubMed Web of Science ®Google Scholar
• MILES D, IBRAHIM N, ROCHE H et al.: i An international, randomized Phase III clinical trial of STn-KLH (Theratope®) therapeutic cancer vaccine in metastatic breast cancer patients. Breast Cancer Res. Treat. i (2003) 82:S17 (Abstract 39).
   Google Scholar
• MILES D, PAPAZ/S/SK: Rationale for the clinical development of STn-KLH (Theratope (R)) and anti-MUC-1 vaccines in breast cancer. Clin. Breast Cancer i (2003) 3:S134–S138.
   Google Scholar
• MAMOUNAS EP, BRYANT J, LEMBERSKY BC et al.: i Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc. Am. Soc. Clin. Oncol i (2003) 22:4 (Abstract 12).
   Google Scholar
• HENDERSON IC, BERRY DA, DEMETRI GD et al.: i Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Clin. Oncol i (2003) 21:976–983.
   PubMedGoogle Scholar
• EARLY BREAST CANCER TRIALISTS'COLLABORATIVE GROUP: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet i (1998) 352:930–942.
   PubMed Web of Science ®Google Scholar
• COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: i Multinational study of the efficacy and safety of humanized anti-HERZ monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Clin. Oncol. i (1999) 17:2639–2648.
   PubMed Web of Science ®Google Scholar
• GLOECKLER RIES LA, REICHMAN ME, LEWIS DR et al: i Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist i (2003) 8:541-552. Websites
   Google Scholar
• http://www.abstracts2view.com/bcs03/search. php?query=Goss &where [1=authors &search =do GOSS PE, INGLE JN, MARTINO S et al.: i Randomized placebo-controlled trial of letrozole in postmenopausal women with early breast cancer completing five years of tamoxifen. 2ffh San Antonio Breast Cancer Symposium, i 2003 (Abstract 42).
   Google Scholar
• http://www.abstracts2view.com/bcs03/search. php?query=Martin&where []=authors &sear ch=do MARTIN M, PIENKOWSKI T, MACKEY J et al.: i TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. 2ffh San Antonio Breast Cancer Symposium, 2003 (Abstract 43).
   Google Scholar
• http://www.abstracts2view.com/bcs03/session index?p=2 O'SHAUGHNESSY J, TJULANDIN S, DAVIDSON N et al: i ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy versus taxol in MBC: a Phase III trial. 26h San Antonio Breast Cancer Symposium, i 2003 (Abstract 44). Affiliation Filippo Montemurrot, Massimo Aglietta tAuthor for correspondence Department of Medical Oncology, Institute for Cancer Research and Treatment, Str. Provinciale 142, 10060 Candiolo, Torino, Italy Tel: +39 (011) 9933250; Fax: +39 (011) 9933275; E-mail: [email protected]
   Google Scholar